WO2013085371A1 - 세포의 유용물질을 상온에서 안정하게 보존하는 방법 - Google Patents
세포의 유용물질을 상온에서 안정하게 보존하는 방법 Download PDFInfo
- Publication number
- WO2013085371A1 WO2013085371A1 PCT/KR2012/010717 KR2012010717W WO2013085371A1 WO 2013085371 A1 WO2013085371 A1 WO 2013085371A1 KR 2012010717 W KR2012010717 W KR 2012010717W WO 2013085371 A1 WO2013085371 A1 WO 2013085371A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- lyophilized
- room temperature
- protective agent
- stably
- Prior art date
Links
- YREDGGKTJQYKIW-QOGYZBMUSA-N CC(C)/N=C\C([C@@H]1C)N1C1CC1 Chemical compound CC(C)/N=C\C([C@@H]1C)N1C1CC1 YREDGGKTJQYKIW-QOGYZBMUSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Definitions
- the present invention relates to a method of lyophilizing a cell to stably preserve the cell and useful substances contained in the cell at room temperature.
- Lyophilization is a drying method in which a sample in a solution state or the like is frozen and left in the same state under reduced pressure to sublimate and remove moisture in the sample, and is widely used for drying a sample including water, including a biological sample.
- samples containing water such as cells, crystallize while freezing solutes or admixtures of water molecules during freezing to form ice crystals consisting solely of water molecules. It is known to diffuse unevenly and freeze concentration occurs.
- damage to the cells can also occur in a dry state at room temperature.
- a cryopreservation solution is used for preservation without damaging cell structure during lyophilization.
- the cryopreservation solution which is used in advance for cell protection before lyophilization, is a buffer solution that maintains the ionic strength and osmotic pressure of the solution, and lyophilization which prevents physical and chemical damage of tissues and prevents structural changes of tissues when freezing and drying. It consists of a protective agent.
- the freeze-drying protector increases the glass transition temperature to prevent tissue breakdown caused by the recrystallization of ice particles in the freeze-drying process, and enhance the stability of the tissue.
- the temperature of the tissue during drying is higher than the glass transition temperature, recrystallization of the ice particles occurs, and the recrystallized ice particles become larger and the tissue is damaged.
- the higher specific gravity of the glass ice or square ice which is stable and small in size of ice crystals, can cause less damage to the tissue and speed up drying.
- lyophilizers are dimethylsulfoxide, dextran, sucrose, glycerol, mannitol, sorbitol, fructose and trehalose. , Raffinose, serum albumin, etc. are combined according to the purpose, but their biosafety has already been verified, but due to the difficult mixing conditions according to the purpose, the manufacturing method is complicated, and a large cost in the manufacturing This takes a disadvantage.
- Lyophilization of bacteria, viruses, serum, vaccines, etc. using the lyophilized protective agent has the advantage of long-term storage at room temperature.
- the lyophilized cells should be stored at freezing and low temperature, and there is a disadvantage in that the useful substances contained in cells and cells cannot be stably stored at room temperature.
- the present invention is to provide a method for stably preserving cells and useful materials contained in cells by lyophilizing the cells at room temperature and a stable lyophilized preparation prepared by the above method.
- the present invention (1) culturing animal cells; (2) treating the cultured animal cells with a lyophilized protective agent; And (3) freeze-drying the animal cells treated with the lyophilized protective agent.
- the present invention also provides a stable lyophilized formulation prepared by the above method.
- Figure 4 shows the form of the keratinocytes in the form of a sheet attached to the PET film.
- Figure 6 shows the results of measuring the protein expressed in the keratin cells and wound healing factors.
- Figure 7 shows the results of measuring the protein expressed in the keratin cells of the pellet form and wound healing factors.
- the present invention (1) culturing animal cells; (2) treating the cultured animal cells with a lyophilized protective agent; And (3) freeze-drying the animal cells treated with the lyophilized protective agent.
- Animal cells of the present invention can be used derived from mammals or humans.
- the cells may be keratinocytes or fibroblasts, and the cells may be in the form of sheets or pellets.
- the pellet-type cells are cells remaining after centrifugation of the suspension cells to remove the supernatant, and the pellet-type cells may include suspension cells.
- tissue of origin of keratinocytes are suitable as the tissue of origin of keratinocytes. If the tissue of origin is skin, it is preferred to use those derived from foreskin, armpits, buttocks, breasts, scalp, pubis or scrotum. If the tissue of origin is a skin appendage, it is suitable to use one derived from hair follicles, sweat glands, sebaceous glands or capillaries. Hair follicles are preferably derived from hair follicles of anagen and are preferably used with hairs attached to keratinocytes of hair follicles.
- Animal cells of the invention are treated with a lyophilized protective agent before lyophilization.
- Sugars used in the present invention include all monosaccharides, disaccharides, polysaccharides, dextrose, maltose, glucose, lactose, sucrose, trehalose, mannose (mannose), raffinose, cellobiose, gentiobiose, isomaltose, arabinose, fructose, melezitose, meliviose melibiose, sorbitol, and triose, but are not limited thereto.
- the lyophilized protective agent of the present invention may comprise a protein.
- Proteins of the invention prevent cells from breaking from freezing. Suitable proteins include, but are not limited to albumin, serum, and the like.
- the protein to be added may be arbitrarily selected according to the type of cell, etc., and may be included in 1 to 15% of the total composition of the lyophilized protective agent. If the protein is less than 1%, the effect is reduced during lyophilization, and if it exceeds 15%, it can affect the measurement experiment of useful substances contained in the cells.
- Treatment of the lyophilized protective agent to the cells in the present invention can be made according to various methods known in the art.
- the treatment time may vary depending on the type of the cell, for example, may be treated for 5 minutes to 10 minutes at room temperature (15 °C to 25 °C).
- the cells were placed in a suitable container and suspended in a buffer solution, and then placed in a cryogenic freezer, frozen at -15 ° C or lower for about 12 hours or more; (2) the sample chamber of the lyophilizer was lowered to ⁇ 15 ° C., and the frozen sample of (1) was added thereto and stabilized for at least 30 minutes; (3) the lyophilizer moisture trap temperature is maintained at ⁇ 70 ° C. to ⁇ 80 ° C. and the vacuum pressure is adjusted to 10 to 100 mtorr, and then the drying is completed while raising the freeze dryer chamber temperature to 25 ° C .; (4) Remove the container from the lyophilizer and seal it with a stopper to store at room temperature.
- Human-derived keratinocytes were cultured pre-confluent at 37 ° C. and 10% CO 2 using a culture medium based on Keratinocyte-Serum Free Medium. The morphology of the cells was observed at a magnification of 100 times using a phase contrast inverted microscope (see FIG. 2).
- Human-derived fibroblasts were cultured pre-confluent at 37 ° C. and 10% CO 2 using a culture medium based on Ham-F12. The morphology of the cells was observed at a magnification of 100 times using a phase contrast inverted microscope (see FIG. 3).
- Keratin cells in the form of a sheet cultured in a) was supported by attaching to a PET film (PET film, polyethylene terephthalate film) (see Fig. 4).
- PET film polyethylene terephthalate film
- Sugars such as glucose 0.1-5%, sucrose 0.1-5%, dextran 0.1-5%, raffinose 0.1-5%, and albumin 0.1-5%, serum 1-10% were added to DMEM (Dulbecco's Modified Eagle's Medium) medium.
- DMEM Dulbecco's Modified Eagle's Medium
- a freeze-preserved solution was prepared by adding a polymer of polyethylene glycol (polyethylene glycol, PEG, molecular weight: 6,000 to 35,000) at a concentration of 0.5% to 5%.
- the cells in the sheet form were added with DMEM (Dulbecco's Modified Eagle's Medium) to the degree of immersion and the remaining culture solution was washed (washed) and added to soak the lyophilized stock solution for 5 to 10 minutes.
- Pellet-type cells were washed with the remaining culture by centrifugation after pipetting by adding 40 mL of PBS to a pellet contained in a 50 mL tube. Repeated a total of three times, and added to the pellet remaining in the 50mL tube to the degree of immersion immersed in a pipette (pipetting) by treatment for 5 to 10 minutes and centrifuged to remove the supernatant.
- the percentage of water removed after lyophilization was calculated by weighing the cells before and after lyophilization. Both the sheet cells and the pellet cells showed a water removal rate of 98% or more when lyophilized by the method of 'Example 3'.
- Experimental group of wounds with 1.5cm diameter on the back of mouse (Balb / c) was used as experimental group 1) Cells before lyophilization supported by vaseline gauze after treatment with freezing preservative solution and 2) Freeze drying preservation solution After the lyophilized cells were applied, and as a control, 1) vaseline gauze and 2) PET film were applied to measure the extent of wound healing after 7 days, 10 days, 14 days and 21 days, respectively. As shown in FIG. 9, the wound healing progressed faster than the control group in both the cells before lyophilization and the cell group after lyophilization.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mechanical Engineering (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
- (1) 동물세포를 배양하는 단계; (2) 상기 배양된 동물세포를 동결건조 보호제로 처리하는 단계; 및 (3) 상기 동결건조 보호제로 처리된 동물세포를 동결건조시키는 단계를 포함하는 동결건조된 세포를 상온에서 안정하게 보존하는 방법.
- 제1항에 있어서, 상기 동물세포는 인간 유래의 세포인 것을 특징으로 하는 동결건조된 세포를 상온에서 안정하게 보존하는 방법.
- 제2항에 있어서, 상기 세포는 케라티노사이트 또는 섬유아세포인 것을 특징으로 하는 동결건조된 세포를 상온에서 안정하게 보존하는 방법.
- 제1항에 있어서, 상기 동결건조 보호제는 당, 단백질, 수용성 고분자 물질을 포함하는 것을 특징으로 하는 동결건조된 세포를 상온에서 안정하게 보존하는 방법.
- 제4항에 있어서, 상기 당은 덱스트로스(dextrose), 말토스(maltose), 글루코스(glucose), 락토스(lactose), 수크로스(sucrose), 트레할로스(trehalose), 만노스(mannose), 라피노스(raffinose), 셀로비오스(cellobiose), 겐티오비오스(gentiobiose), 이소말토스(isomaltose), 아라비노스(arabinose), 과당(fructose), 멜레디토스(melezitose), 멜리비오스(melibiose), 소비톨(sorbitol), 트리오스(triose)에서 선택되는 것을 특징으로 동결건조된 세포를 상온에서 안정하게 보존하는 방법.
- 제4항에 있어서, 상기 단백질은 알부민 또는 혈청인 것을 특징으로 하는 동결건조된 세포를 상온에서 안정하게 보존하는 방법.
- 제4항에 있어서, 상기 수용성 고분자 물질은 폴리에틸렌 글리콜 또는 프로필렌글리콜, HES(hydroxyethyl starch), 폴리비닐피롤리돈, 폴리아크릴아마이드, 폴리에틸렌아민, 폴리에틸렌옥사이드(polyethylene oxide), 피콜(Ficoll)에서 선택되는 것을 특징으로 하는 동결건조된 세포를 상온에서 안정하게 보존하는 방법.
- 제1항 내지 제7항 중 어느 한 항의 방법으로 제조된 안정한 동결건조 제제.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/364,056 US20140356948A1 (en) | 2011-12-09 | 2012-12-10 | Method for Stably Preserving Useful Substances of Cells at Room Temperature |
JP2014545829A JP2015500029A (ja) | 2011-12-09 | 2012-12-10 | 細胞の有用物質を常温で安定して保存する方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0132135 | 2011-12-09 | ||
KR1020110132135A KR101410065B1 (ko) | 2011-12-09 | 2011-12-09 | 세포의 유용물질을 상온에서 안정하게 보존하는 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013085371A1 true WO2013085371A1 (ko) | 2013-06-13 |
Family
ID=48574641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/010717 WO2013085371A1 (ko) | 2011-12-09 | 2012-12-10 | 세포의 유용물질을 상온에서 안정하게 보존하는 방법 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20140356948A1 (ko) |
JP (1) | JP2015500029A (ko) |
KR (1) | KR101410065B1 (ko) |
WO (1) | WO2013085371A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110093403A (zh) * | 2019-03-19 | 2019-08-06 | 融智生物科技(青岛)有限公司 | 荧光pcr试剂的冻干保护剂以及冻干芯片的制备方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101596581B1 (ko) * | 2014-06-18 | 2016-02-23 | 전세화 | 조직재생물질 방출 유도형 세포치료제 조성물 및 그의 제조방법 |
CA2988610A1 (en) * | 2015-06-10 | 2016-12-15 | Cellphire, Inc. | Composition and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia |
US10448631B2 (en) | 2015-09-22 | 2019-10-22 | East Carolina University | Cryopreservation using sucralose |
DE112017007639T5 (de) * | 2017-06-13 | 2020-06-04 | Chung Chin SUN | Neues verfahren zum blutplasmaprotein-aktivitätserhalt |
WO2019099427A1 (en) * | 2017-11-14 | 2019-05-23 | The University Of North Carolina At Chapel Hill | Compositions and methods for stabilization of proteins |
CA3121484A1 (en) | 2018-11-30 | 2020-06-04 | Cellphire, Inc. | Platelets loaded with anti-cancer agents |
WO2020112963A1 (en) | 2018-11-30 | 2020-06-04 | Cellphire, Inc. | Platelets as delivery agents |
AU2020267368B2 (en) | 2019-05-03 | 2023-05-04 | Cellphire, Inc. | Materials and methods for producing blood products |
KR20220054329A (ko) | 2019-08-16 | 2022-05-02 | 셀파이어, 인크. | 항혈소판제 역전제로서 트롬보솜 |
EP4027785A1 (en) * | 2019-09-13 | 2022-07-20 | Lonza Ltd. | Method of producing lyophilized cells |
KR102116954B1 (ko) * | 2019-12-26 | 2020-05-29 | 주식회사 엠케이바이오텍 | 태아 유래 줄기세포의 동결 보존 및 동결 건조용 배지 조성물 |
WO2021158645A1 (en) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets |
CN113396894A (zh) * | 2021-07-06 | 2021-09-17 | 南方医科大学南方医院 | 适用于单位毛囊保存的复合冻存液及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018504A1 (en) * | 1990-05-25 | 1991-12-12 | Cryopharm Corporation | Process for lyophilizing cells, cell-like materials and platelets in a mixture of biocompatible amphipathic polymers |
US5670308A (en) * | 1992-12-04 | 1997-09-23 | Development Biotechnological Processes Snc Di Pelliccia Maria Teresa | Cryoprotective aqueous solutions useful for the preservation of in vitro cultured epithelial sheets |
KR20040065208A (ko) * | 2001-08-09 | 2004-07-21 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 진핵 세포 및 세포 보존 방법 |
US7935478B2 (en) * | 2004-02-02 | 2011-05-03 | Core Dynamics Limited | Biological material and methods and solutions for preservation thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0522134A1 (en) * | 1991-01-11 | 1993-01-13 | COBE Laboratories, Inc. | Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material |
WO1993000807A1 (en) * | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
JP3311351B2 (ja) * | 1991-11-20 | 2002-08-05 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 新規なケラチノサイト培養物,その調製方法及び創傷治療物質としてのその用途 |
AU672775B2 (en) * | 1992-01-21 | 1996-10-17 | Cobe Laboratories Inc. | Method of freezing cells and cell-like materials |
US5750330A (en) * | 1996-06-19 | 1998-05-12 | Litron Laboratories | Method and composition for lyophilizing red blood cells |
WO2004110372A2 (en) * | 2003-05-30 | 2004-12-23 | Stratatech Corporation | Room temperature storage of organs |
GB0812041D0 (en) * | 2008-07-02 | 2008-08-06 | Enigma Diagnostics Ltd | Compositions |
US9598676B2 (en) * | 2009-07-13 | 2017-03-21 | Bharat Biotech International Limited | Composition useful as rotavirus vaccine and a method therefor |
-
2011
- 2011-12-09 KR KR1020110132135A patent/KR101410065B1/ko active IP Right Grant
-
2012
- 2012-12-10 WO PCT/KR2012/010717 patent/WO2013085371A1/ko active Application Filing
- 2012-12-10 JP JP2014545829A patent/JP2015500029A/ja active Pending
- 2012-12-10 US US14/364,056 patent/US20140356948A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018504A1 (en) * | 1990-05-25 | 1991-12-12 | Cryopharm Corporation | Process for lyophilizing cells, cell-like materials and platelets in a mixture of biocompatible amphipathic polymers |
US5670308A (en) * | 1992-12-04 | 1997-09-23 | Development Biotechnological Processes Snc Di Pelliccia Maria Teresa | Cryoprotective aqueous solutions useful for the preservation of in vitro cultured epithelial sheets |
KR20040065208A (ko) * | 2001-08-09 | 2004-07-21 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 진핵 세포 및 세포 보존 방법 |
US7935478B2 (en) * | 2004-02-02 | 2011-05-03 | Core Dynamics Limited | Biological material and methods and solutions for preservation thereof |
Non-Patent Citations (1)
Title |
---|
LIU, Y. ET AL.: "Effect of various freezing solutions on cryopreservation of mesenchymal stem cells from different animal species", CRYO LETTERS, vol. 32, no. 5, September 2011 (2011-09-01), pages 425 - 435 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110093403A (zh) * | 2019-03-19 | 2019-08-06 | 融智生物科技(青岛)有限公司 | 荧光pcr试剂的冻干保护剂以及冻干芯片的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2015500029A (ja) | 2015-01-05 |
US20140356948A1 (en) | 2014-12-04 |
KR20130065323A (ko) | 2013-06-19 |
KR101410065B1 (ko) | 2014-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013085371A1 (ko) | 세포의 유용물질을 상온에서 안정하게 보존하는 방법 | |
WO2011105663A1 (ko) | 무세포 진피 기질의 제조 방법 및 그로부터 제조된 무세포 진피 기질 | |
Marquez-Curtis et al. | Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects | |
AU2013351058B2 (en) | Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation | |
CN109090100A (zh) | 一种间充质干细胞冻存液及其制备方法与使用方法 | |
CN108617638B (zh) | 组织和/或细胞冻存保护液及其制备与应用 | |
CN104560870B (zh) | 一种制备蜕膜间充质干细胞的方法 | |
US20230257696A1 (en) | Placenta-derived matrix and methods of preparing and use thereof | |
US20120276581A1 (en) | Method for preserving cancellous bone samples and preserved cancellous bone tissue | |
US20210002606A1 (en) | Extracellular matrix composition beads for cell culture | |
CN106109496A (zh) | 人脐带间充质干细胞提取物冻干粉及制备方法 | |
CA2256333A1 (en) | Long-term shelf preservation by vitrification | |
CN108159078A (zh) | 一种细胞生长因子冻干粉、制备方法及应用 | |
WO2013089434A1 (ko) | 상처 치유용 드레싱재 | |
WO2015194872A1 (ko) | 조직재생물질 방출 유도형 세포치료제 조성물 및 그의 제조방법 | |
WO2017223520A1 (en) | Viable lyophilized compositions derived from human tissues and methods of making the same | |
CN113729006A (zh) | 一种猪种种质资源的快速保存方法 | |
CN108938669A (zh) | 一种用于治疗皮肤损伤的干细胞软膏及其制备方法 | |
WO2019035925A1 (en) | COMPOSITION AND METHOD FOR TREATING SKIN AFFECTION | |
CN113171332A (zh) | 一种外泌体冻干粉、其制备方法及护肤品 | |
WO2016006782A1 (ko) | 줄기세포의 보관 안정성 증진용 조성물 | |
WO2019103529A2 (ko) | 세포 동결 보존용 조성물 및 이를 이용한 세포 동결 보존 방법 | |
WO2018190613A1 (ko) | 하이드로겔화 되는 창상 치료용 파우더 조성물 및 이의 제조방법 | |
WO2021132810A1 (ko) | 태아 유래 줄기세포의 동결 보존 및 동결 건조용 배지 조성물 | |
KR20170136212A (ko) | 줄기세포 성장인자를 포함하는 동결건조 조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12856352 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014545829 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14364056 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12856352 Country of ref document: EP Kind code of ref document: A1 |